Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Contributed by: Business Wire

Logo

Tags

Science

Neurology

Biotechnology

Research

Pharmaceutical

Finance

Health

Professional Services

Acorda Therapeutics

More Like This

Business Wire associated0

Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Merz Therapeutics Hosts Over 300 International Healthcare Professionals at its First Global “Merz Expert Connect Summit 2023”

Merck operators monitoring viral vector production in a bioreactor in Merck's Carlsbad, California manufacturing facility. (Photo: Business Wire)

Merck Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector Manufacturing

PR Newswire associated0

Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million

PR Newswire associated0

Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk

PR Newswire associated0

CordenPharma Invests €900m in Transformational Peptide Platform Expansion in the USA & Europe

ONWARD® Medical Successfully Raises EUR 50 Million in an Upsized Capital Increase with Cornerstone Investment from Ottobock SE & Co. KGaA

ONWARD® Medical Launches Capital Increase for Indicative Amount of c. EUR 40 Million including EUR 22.5 Million Cornerstone Investment from Ottobock SE & Co. KGaA